Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Riccardo De Giorgi

MD, DPhil, MRCPsych

Clinical Lecturer

  • Clinical Lecturer ST4-6 in General Adult Psychiatry

Repurposing drugs in mood disorders

I am a Clinical Lecturer at the University of Oxford, Department of Psychiatry, and ST4-6 at Health Education England-Thames Valley, Oxford Health NHS Foundation Trust. I am the academic representative for the European Federation of Psychiatric Trainees programme in Oxford and the Oxford Clinical-Academic Journal Club. I am a tutor in psychiatry and regularly teach medical students and trainees about the topics of research methodology and critical appraisal, psychopharmacology, and mood disorders.

I am interested in the neuropsychopharmacology and evidence-based treatment of mental illness, especially mood disorders. I am fascinated by the problem of "treatment resistance", i.e., when patients do not appear to respond to several lines of therapy. There is increasing evidence that immunological and metabolic factors play a role in the pathophysiology of depression, especially in patients who are treatment-resistant. Repurposing commonly used medical treatments (e.g., anti-inflammatory medications) may therefore  benefit those patients who respond poorly to conventional antidepressants and who might be identifiable a priori through measurement of inflammatory and metabolic markers.

Currently, I am working on experimental medicine studies for the repurposing of drugs with immuno-metabolic activity (e.g., statins, GLP1-RAs) in mood disordersI look at early markers of antidepressant response, such as changes in emotional processing, reward, and immuno-metabolic peripheral markers to validate the use of these drugs in further clinical trials.